Zonisamide (All indications)

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Källén (Zonisamide) (Controls unexposed, NOS) (Indications NOS), 2013 Meador (Zonisamide) (Controls unexposed, sick), 2020 The Australian Pregnancy Register of Antiepileptic Drugs (Mixed indications) (Controls unexposed, sick), 2024 Battino (Zonisamide) (Epilepsy), 2024 The UKIEPR (Epilepsy) (Controls unexposed, sick), 2024 The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls unexposed, sick), 2024 The NAAED (Zonisamide) (Controls unexposed, disease free) (Indications NOS), 2025 71.69[0.75; 3.79]49,667325not evaluable Major congenital malformations Källén (Zonisamide) (Controls unexposed, NOS) (Indications NOS), 2013 Meador (Zonisamide) (Controls unexposed, sick), 2020 The Australian Pregnancy Register of Antiepileptic Drugs (Mixed indications) (Controls unexposed, sick), 2024 Battino (Zonisamide) (Epilepsy), 2024 The UKIEPR (Epilepsy) (Controls unexposed, sick), 2024 The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls unexposed, sick), 2024 The NAAED (Zonisamide) (Controls unexposed, disease free) (Indications NOS), 2025 71.69[0.75; 3.79]49,667325not evaluable Growth parameters and prematurity Low birth weight (< 2500g) Hernández-Díaz (Zonisamide) (Controls unexposed, disease free), 2014 12.17[0.91; 5.14]2698not evaluable Preterm (< 37 weeks) The NAAED (Zonisamide) (Controls unexposed, disease free) (Indications NOS), 2025 10.76[0.49; 1.18]215228not evaluable Small for gestational age (weight) Hernández-Díaz (Zonisamide), 2017 11.90[1.20; 3.00]-125not evaluable Intrauterine deaths Intrauterine deaths (as a whole or unspecified) Meador (Zonisamide) (Controls unexposed, sick), 2020 11.16[0.02; 62.85]-13not evaluable Neuro-developmental disorders Language disorders/delay Meador (Zonisamide) (Controls unexposed, disease free), 2021 Straub (Controls unexposed, sick) (Zonisamide) (Epilepsy), 2026 20.66[0.22; 2.01]469257not evaluable ADHD (Attention deficit hyperactivity disorder): Diagnosis Straub (Controls unexposed, sick) (Zonisamide) (Epilepsy), 2026 10.93[0.48; 1.80]357246not evaluable ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk Straub (Controls unexposed, sick) (Zonisamide) (Epilepsy), 2026 10.93[0.48; 1.80]357246not evaluable ASD (Autism spectrum disorder): Diagnosis Straub (Controls unexposed, sick) (Zonisamide) (Epilepsy), 2026 10.92[0.28; 3.00]97246not evaluable ASD (Autism spectrum disorder): Diagnosis/Risk Straub (Controls unexposed, sick) (Zonisamide) (Epilepsy), 2026 10.92[0.28; 3.00]97246not evaluable Cognitive developmental disorders/delay (3-6 years old) Straub (Controls unexposed, sick) (Zonisamide) (Epilepsy), 2026 13.62[0.81; 16.21]17246not evaluable Learning disorders Straub (Controls exposed to LTG) (Zonisamide) (Epilepsy), 2026 10.53[0.03; 9.00]12246not evaluable Psychomotor developmental disorders/delay Straub (Controls unexposed, sick) (Zonisamide) (Epilepsy), 2026 10.74[0.18; 3.10]82246not evaluable Severe cognitive developmental delay (Mental retardation) (3-6 years old) Straub (Controls unexposed, sick) (Zonisamide) (Epilepsy), 2026 13.62[0.81; 16.21]17246not evaluable0.0100.01.0

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons